Revenio Group Corporation, Stock Exchange Release, January 2, 2017 at 15:00
CHANGES IN BOARDS OF REVENIO GROUP CORPORATION'S SUBSIDIARIES
The composition of the Board of Directors will change in Revenio Group Corporation's subsidiaries Icare Finland Oy, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.
As announced on 16 May 2016, Olli-Pekka Salovaara, Revenio Group Corporation's long-term President & CEO resigned on 31 December 2016. At the same time, he resigned from board membership in the above-mentioned subsidiaries.
Timo Hildén, who assumed the position of the Group's new President & CEO on 1 January 2017 and has been a deputy member on the boards of Icare Finland Oy, Revenio Research Oy and Done Medical Oy will become an ordinary member of these boards, and Robin Pulkkinen, the Group's CFO, will be appointed a deputy member of the boards. Tomi Karvo, Icare Finland Oy's Sales and Marketing Director, has been appointed a new member of Oscare Medical Oy's Board of Directors, and Timo Hildén has been appointed Chairman of the Board of Directors.
Revenio Group Corporation Timo Hildén President & CEO
For further information, please contact:
Timo Hildén, President & CEO, tel. +358 40 580 4774 timo.hilden@revenio.fi www.revenio.fi
DISTRIBUTION:
NASDAQ Helsinki Financial Supervisory Authority Principal media www.revenio.fi
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2015, Revenio Group's net sales totaled MEUR 20.3, with its operating margin for continuing operations standing at 28.4%. Revenio Group Corporation is listed on Nasdaq Helsinki.
